FRIDAY, NOVEMBER 30

6:00 p.m.-7:00 p.m. OPENING KEYNOTE SESSION
Harbor Ballroom II and III

Welcome remarks and keynote introduction
Lewis C. Cantley, Cornell Medical College, New York-Presbyterian Hospital, New York, NY

PI3Kinase inhibitors: Challenges and lessons learned in clinical development
Samit Hirawat, Novartis, East Hanover, NJ
(not eligible for CME credit)

7:00 p.m.-9:00 p.m. WELCOME RECEPTION
Harbor Ballroom I

SATURDAY, DECEMBER 1

7:30 a.m.-8:30 a.m. CONTINENTAL BREAKFAST
Harbor Ballroom I

8:30 a.m.-10:00 a.m. PLENARY SESSION 1: BIOLOGY OF THE PI3K/MTOR PATHWAY
Harbor Ballroom II and III

Session Chair: David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, MA

8:30 a.m.-9:00 a.m. The PI3K-mTOR signaling network and tumor cell metabolism
Brendan D. Manning, Harvard School of Public Health, Boston, MA

9:00 a.m.-9:30 a.m. Regulation of growth by the mTOR pathway
David M. Sabatini

9:30 a.m.-10:00 a.m. Stroma-driven resistance to PI3K/mTOR inhibition
Taru E. Muranen, Beth Israel Deaconess Medical Center, Boston, MA

10:00 a.m.-10:30 a.m. BREAK
Harbor Ballroom Foyer
CONFERENCE PROGRAM

10:30 a.m.-12:15 p.m.  PLENARY SESSION 2: AUTOPHAGY AND METABOLISM
Harbor Ballroom II and III

Session Chair: Eileen P. White, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

10:30 a.m.-11:00 a.m.  Autophagy and cancer metabolism
Eileen P. White

11:00 a.m.-11:30 a.m.  Identifying metabolic dependencies in pancreatic cancer
Alec C. Kimmelman, New York University Langone Medical Center, New York, NY

11:30 a.m.-12:00 p.m.  Pooled CRISPR screens for novel autophagy-related factors identify TMEM41, an ER-resident protein predicted to be a channel
Vlad Denic, Harvard University, Cambridge, MA

12:00 p.m.-12:15 p.m.  Phosphorylation of DEPDC5 by the Pim-1 protein kinase, a cancer driver, stimulates mTORC1 activity by regulating the DEPDC5-Rag GTPase interaction*
Sathish Padi, University of Arizona Cancer Center, The University of Arizona, Tucson, AZ

12:15 p.m.-2:30 p.m.  FREE TIME (LUNCH ON OWN)

2:30 p.m.-4:15 p.m.  PLENARY SESSION 3: STRUCTURAL BIOLOGY
Harbor Ballroom II and III

Session Chair: Roger L. Williams, MRC Laboratory of Molecular Biology, Cambridge, MA

2:30 p.m.-3:00 p.m.  Control of PIP3 levels by PI3Kα and PTEN
L. Mario Amzel, Johns Hopkins University School of Medicine, Baltimore, MD

3:00 p.m.-3:30 p.m.  Structure and dynamics of Rag heterodimers in a complex with mTORC1
Roger L. Williams

3:30 p.m.-3:45 p.m.  Structural and functional analyses of GATOR1, a negative regulator of the mTORC1 pathway*
Kuang Shen, Whitehead Institute for Biomedical Research, Cambridge, MA

3:45 p.m.-4:00 p.m.  Selective degradation of mutant PIK3CA promotes increased mutant specificity in a subset of PI3K ATP-competitive inhibitors*
Nicholas Endres, Genentech, South San Francisco, CA

4:00 p.m.-4:15 p.m.  4EBP1 reactivation by potent and selective bisteric inhibitors of mTORC1*
Nidhi Tibrewal, Revolution Medicines, Redwood City, CA

4:30 p.m.-6:30 p.m.  POSTER SESSION A / RECEPTION
Harbor Ballroom I

*Short talk from proffered abstract

TARGETING PI3K/mTOR SIGNALING
**SUNDAY, DECEMBER 2**

7:00 a.m.-8:00 a.m.  **CONTINENTAL BREAKFAST**  
Harbor Ballroom I

8:00 a.m.-9:45 a.m.  **PLENARY SESSION 4: TRANSLATIONAL CONTROL OF CANCER**  
Harbor Ballroom II and III  
**Session Chair: Davide Ruggerio**, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

8:00 a.m.-8:30 a.m.  
**Translating the cancer genome one codon at a time and its therapeutic implications**  
Davide Ruggero

8:30 a.m.-9:00 a.m.  
**Coordination of mRNA processing, translation, and metabolism by mTORC1**  
John Blenis, Weill Cornell Medical College, New York, NY

9:00 a.m.-9:30 a.m.  
**An mTOR/eIF4E-independent translation mechanism promotes breast cancer metastasis**  
Robert J. Schneider, New York University School of Medicine, New York, NY

9:30 a.m.-9:45 a.m.  
**Regulation of mRNA N6-adenosine methylation by the mTOR signaling**  
Gina Lee, Weill Cornell Medicine, New York, NY

9:45 a.m.-10:15 a.m.  **BREAK**  
Harbor Ballroom Foyer

10:15 a.m.-12:00 p.m.  **PLENARY SESSION 5: IMMUNOLOGY**  
Harbor Ballroom II and III  
**Session Chair: Jonathan D. Powell**, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

10:15 a.m.-10:45 a.m.  
**mTOR as a central regulator of T-cell activation, differentiation, and function**  
Jonathan D. Powell

10:45 a.m.-11:15 a.m.  
**Title to be announced**  
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN

11:15 a.m.-11:45 a.m.  
**Role of PI3K signaling in T-cell-mediated immune responses**  
Laurence A. Turka, Rheos Medicines, Cambridge, MA

11:45 a.m.-12:00 p.m.  
**Developmentally regulated mTOR degradation in normal and malignant hematopoiesis**  
Christina Spevak, NYU Health, New York, NY

*Short talk from proffered abstract*
CONFERENCE PROGRAM

12:00 p.m.-2:15 p.m.  POSTER SESSION B / LUNCH  Harbor Ballroom I

2:15 p.m.-4:30 p.m.  PLENARY SESSION 6: PI3K/MTOR IN LIQUID TUMORS AND IMMUNITY  Harbor Ballroom II and III

  Session Chair:  Kira Gritsman, Albert Einstein College of Medicine, New York, NY

  2:15 p.m.-2:45 p.m.  Strategies to target the mTORC1/EIF4F axis in B-cell leukemia and lymphoma  David A. Fruman, University of California, Irvine, Irvine, CA

  2:45 p.m.-3:15 p.m.  The PI3 isoforms in myeloid leukemia and hematopoietic stem cells  Kira Gritsman

  3:15 p.m.-3:45 p.m.  PI3Kgamma control of antitumor immunity  Judith A. Varner, UCSD Moores Cancer Center, La Jolla, CA

  3:45 p.m.-4:00 p.m.  Pancreatic ductal adenocarcinoma requires PI3Kalpha activity to accelerate circulating DNA-positive metastatic disease*  Julie Guillermet-Guibert, Inserm, Cancer Research Center of Toulouse, Toulouse, France

  4:00 p.m.-4:15 p.m.  AKT mutant allele-specific activation dictates pharmacologic sensitivities*  Tripti Shrestha Bhattarai, Memorial Sloan Kettering Cancer Center, New York, NY

  4:15 p.m.-4:30 p.m.  Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials*  Zhenghe (John) Wang, Case Western Reserve University, Cleveland, OH

MONDAY, DECEMBER 3

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST  Harbor Ballroom I

8:00 a.m.-10:00 a.m.  PLENARY SESSION 7: PRECLINICAL MODELS FOR DRUG DEVELOPMENT  Harbor Ballroom II and III

  Session Chair:  Jean J. Zhao, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  8:00 a.m.-8:30 a.m.  Integrating immunotherapy and targeted therapy in cancer: From mouse models to human therapy  Jean J. Zhao

  8:30 a.m.-9:00 a.m.  Title to be announced  Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA

*Short talk from proffered abstract
9:00 a.m.-9:30 a.m.  Enhancing responses to targeted therapies through metabolic intervention
Lewis C. Cantley, Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY

9:30 a.m.-10:00 a.m.  PI3K inhibitors as a backbone for combination treatments for breast and ovarian cancer
Gerburg M. Wulf, Beth Israel Deaconess Medical Center, Boston, MA

10:00 a.m.-10:15 a.m.  BREAK
Harbor Ballroom Foyer

10:15 a.m.-12:00 p.m.  PLENARY SESSION 8: TRANSLATION TO THE CLINIC
Harbor Ballroom II and III

Session Chair: Lori S. Friedman, Genentech, Inc., South San Francisco, CA

10:15 a.m.-10:45 a.m.  AKTing to PIK the right patients
Lori S. Friedman

10:45 a.m.-11:15 a.m.  Development of PI3K inhibitors in breast cancer
Cynthia X. Ma, Washington University Siteman Cancer Center, St. Louis, MO

11:15 a.m.-11:45 a.m.  Reprogramming tumor-associated macrophages by targeting PI3K-gamma with IPI-549
Jeffery L. Kutok, Infinity Pharmaceuticals, Cambridge, MA

11:45 a.m.-12:00 p.m.  PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers*
Ecaterina Ileana Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, TX

12:00 p.m.  CLOSING REMARKS / DISCUSSION

*Short talk from proffered abstract